Interventional Oncolytic Immunotherapy with LTX-315 for Residual Tumor after Incomplete Radiofrequency Ablation of Liver Cancer.

Guan-Hui ZhouXuefeng KanFeng ZhangHongxiu JiJunhui SunXiaoming Yang

Published in: Cancers (2022)

Interventional oncolytic immunotherapy with LTX-315 for residual tumors after iRFA of liver cancer is feasible, which may open up new avenues to prevent residual tumors after RFA of intermediate-to-large liver cancers.

Keyphrases

radiofrequency ablation
minimally invasive
young adults
childhood cancer